Nuclera and leadXpro Partner to Accelerate Structure-Based Drug Design for Complex Membrane Proteins
CAMBRIDGE, England & BOSTON & VILLIGEN, Switzerland--(BUSINESS WIRE)--Nuclera, the biotechnology company enabling rapid access to high-quality proteins and leadXpro, a specialist in structure-based ...
Nimbus and Eli Lilly collaborate to develop an oral treatment for obesity, leveraging computational chemistry and structure-based drug design. The partnership builds on previous efforts targeting AMPK ...
In drug discovery, virtual screening is a fast and cost-effective way of narrowing down vast chemical libraries to identify the most promising hits, reducing synthesis and testing requirements while ...
When machine learning is used to suggest new potential scientific insights or directions, algorithms sometimes offer solutions that are not physically sound. Subscribe to our newsletter for the latest ...
For many people, "protein" is the key element of a food order. However, beyond the preferred choice of meats or plant-based ...
Nuclera and leadXpro Partner to Accelerate Structure-Based Drug Design for Complex Membrane Proteins
Partnership will deliver AI-guided end-to-end workflow to access challenging membrane protein targets To de-risk and shorten path to critical structural and biophysical insights that inform ...
Nuclera and leadXpro partner to accelerate structure-based drug design for complex membrane proteins
Nuclera, the biotechnology company enabling rapid access to high-quality proteins and leadXpro, a specialist in structure-based drug discovery for membrane proteins, today announced a scientific ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results